Adastra Pharmaceuticals Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

Adastra Pharmaceuticals General Information

Description

Developer of medicines focused on cancer treatment. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professionals to ensure the survival of their patients and increase their quality of life.

Contact Information

Formerly Known As
Tragara Pharmaceuticals
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 2929 Campus Drive
  • Suite 230
  • San Mateo, CA 94403
  • United States
+1 (760)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 2929 Campus Drive
  • Suite 230
  • San Mateo, CA 94403
  • United States
+1 (760)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adastra Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 07-Sep-2021 Completed Clinical Trials - Phase 1
10. Later Stage VC (Series B) 25-Jan-2021 Cancelled Clinical Trials - Phase 1
9. Later Stage VC (Series B) 24-Apr-2019 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series A) 15-Nov-2016 Completed Pre-Clinical Trials
7. Later Stage VC (Series 3) 01-Sep-2015 Completed Pre-Clinical Trials
6. Later Stage VC (Series 2) 03-Sep-2013 Completed Pre-Clinical Trials
5. Later Stage VC (Series 1) 08-Aug-2012 Completed Pre-Clinical Trials
4. Grant 26-Mar-2010 Completed Pre-Clinical Trials
3. Later Stage VC (Series 1) 04-Feb-2010 $5M $53M Completed Pre-Clinical Trials
2. Early Stage VC (Series 1) 15-Mar-2007 $40M $48M Completed Pre-Clinical Trials
To view Adastra Pharmaceuticals’s complete valuation and funding history, request access »

Adastra Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Series 3
Series 2 3,199,449 $0.000100 $0.32 $4 $4 1x $4 11.24%
Series 1 4,374,998 $0.000100 8% $10 $10 1x $10 15.37%
To view Adastra Pharmaceuticals’s complete cap table history, request access »

Adastra Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medicines focused on cancer treatment. The company's medicines include an oral multi-kinase inhibitor which
Drug Discovery
San Mateo, CA
2 As of 2021

Saint Louis, MO

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adastra Pharmaceuticals Competitors (19)

One of Adastra Pharmaceuticals’s 19 competitors is Euclises, a Venture Capital-Backed company based in Saint Louis, MO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Euclises Venture Capital-Backed Saint Louis, MO
NexImmune Formerly VC-backed Gaithersburg, MD
Amphivena Therapeutics Venture Capital-Backed South San Francisco, CA
Altimmune Corporate Backed or Acquired Gaithersburg, MD
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 19 competitors. Get the full list »

Adastra Pharmaceuticals Patents

Adastra Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2632548-T3 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010
EP-2531197-B1 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010
EP-2531197-A1 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010
EP-2531197-A4 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010
CA-2707424-A1 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders Inactive 28-Nov-2007 A61K31/402
To view Adastra Pharmaceuticals’s complete patent history, request access »

Adastra Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adastra Pharmaceuticals Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Domain Associates Venture Capital Minority
Lightstone Ventures Venture Capital Minority
Mitsubishi International Corporation Minority
Morgenthaler Ventures Venture Capital Minority
Multiple Myeloma Research Foundation Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

Adastra Pharmaceuticals FAQs

  • When was Adastra Pharmaceuticals founded?

    Adastra Pharmaceuticals was founded in 2005.

  • Where is Adastra Pharmaceuticals headquartered?

    Adastra Pharmaceuticals is headquartered in San Mateo, CA.

  • What is the size of Adastra Pharmaceuticals?

    Adastra Pharmaceuticals has 2 total employees.

  • What industry is Adastra Pharmaceuticals in?

    Adastra Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Adastra Pharmaceuticals a private or public company?

    Adastra Pharmaceuticals is a Private company.

  • What is Adastra Pharmaceuticals’s current revenue?

    The current revenue for Adastra Pharmaceuticals is .

  • How much funding has Adastra Pharmaceuticals raised over time?

    Adastra Pharmaceuticals has raised $87.6M.

  • Who are Adastra Pharmaceuticals’s investors?

    Domain Associates, Lightstone Ventures, Mitsubishi International, Morgenthaler Ventures, and Multiple Myeloma Research Foundation are 5 of 8 investors who have invested in Adastra Pharmaceuticals.

  • Who are Adastra Pharmaceuticals’s competitors?

    Euclises, NexImmune, Amphivena Therapeutics, Altimmune, and Inovio Pharmaceuticals are some of the 19 competitors of Adastra Pharmaceuticals.

  • When was Adastra Pharmaceuticals acquired?

    Adastra Pharmaceuticals was acquired on 07-Sep-2021.

  • Who acquired Adastra Pharmaceuticals?

    Adastra Pharmaceuticals was acquired by Percans Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »